MoonLake Immunotherapeutics (MLTX) Free Cash Flow (2021 - 2026)

MoonLake Immunotherapeutics' Free Cash Flow history runs 6 years deep, the most recent figure standing at -$66.3 million for Q1 2026.

• In Q1 2026, Free Cash Flow fell 73.64% year-over-year to -$66.3 million; the TTM figure through Mar 2026 stood at -$224.2 million (down 59.97% YoY), while the FY2025 annual figure was -$196.0 million, down 67.4% from the prior year.
• Free Cash Flow was -$66.3 million for Q1 2026 at MoonLake Immunotherapeutics, down from -$58.8 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of -$9.0 million in Q1 2023 to a low of -$66.3 million in Q1 2026.
• Historically, Free Cash Flow has averaged -$28.1 million across 5 years, with a median of -$20.8 million in 2022.
• Biggest YoY gain for Free Cash Flow was 67.08% in 2022; the steepest drop was 13074.98% in 2022.
• A 5-year view of Free Cash Flow shows it stood at -$11.6 million in 2022, then declined by 8.9% to -$12.6 million in 2023, then slumped by 285.24% to -$48.6 million in 2024, then declined by 20.85% to -$58.8 million in 2025, then declined by 12.74% to -$66.3 million in 2026.
• The last three Free Cash Flow figures came in at -$66.3 million (Q1 2026), -$58.8 million (Q4 2025), and -$44.5 million (Q3 2025), per Business Quant data.